Decision-making in drug development
Date:
12 December 2018
Location:
Servier 50 Rue Carnot, F- 92284 Suresnes France
Description:
Taking decisions during the development of a new drug requires combining many and varying pieces of information. The interconnections between them are often only partially known, reflecting the complexity of the context in which drugs are evaluated and the cognitive load required for health care decisions. Decision-makers need quantitative tools to support informed decisions, with transparent processes that synthesize the whole available information in order to evaluate the success associated to different options.
This meeting aims to bring together statisticians from the pharmaceutical industry and academia to hear about recent advances in statistical methods for quantitative decision-making in drug development
For the event program please Click Here
Event Posters
 Tumour growth model to improve early PFS estimation thereby enhancing phase II go/no decisions - Buchner, Bleckert |
| Predictive Proba of Success Application to an interim analysis - Colin |
| Making an Informed Decision to Ensure an Efficient Patient Recruitment - Debard, Munda, Boulanger, Guilleminot |
| An efficient dev pgm under limited prior info about the association bw response and OS - Gotte, Xiong, Kirchner, Kieser |
| Updating the proba of study success for combination therapies - Graham, Jaki, Harbron |
| Decision making in Multi-Regional CTs using Predictive Proba of Success - Imbert, Chimits, Guedj, Robert, Saint-Hilary |
| Scale Loss Score A new tool for drug benefit-risk assessment - Hilary |